Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Biotage AB (publ)
  6. News
  7. Summary
    BIOT   SE0000454746

BIOTAGE AB (PUBL)

(BIOT)
  Report
Delayed Quote. Delayed Nasdaq Stockholm - 01/28 11:29:55 am
184.3 SEK   +1.65%
01/03Biotage Advances To Nasdaq Stockholm's Large Cap Segment
MT
01/03Biotage moves to the large cap segment
AQ
2021Change in number of shares and votes
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Issue and re-purchase of class C shares for incentive program

11/30/2021 | 09:31am EST

The Board of Directors of Biotage AB (publ) ("Biotage") has today resolved, by virtue of the authorisation by the Annual General Meeting held on April 28, 2021, to issue and immediately thereafter re-purchase 243,252 class C shares. The shares are issued and re-purchased in accordance with the incentive program LTIP 2021 which was adopted by the Annual General Meeting held on April 28, 2021.

Danske Bank A/S, Danmark, Sverige Filial, will subscribe for the entire issue of new class C shares at a subscription price of SEK 1.39 per share, corresponding to the quota value of the shares. The entire issue of class C shares will thereafter, in accordance with the Board of Directors' resolution, be re-purchased by Biotage for the same price. The class C shares will be converted into ordinary shares prior to delivery to qualifying participants of LTIP 2021.

The purpose of the re-purchase is to ensure delivery of shares to participants and to secure social contributions arising as a result of LTIP 2021. The class C shares do not entitle to dividends and each share entitles to 1/10 voting right.

This information was submitted for publication, through the agency of the contact persons set out above, at 15.30 CET, November 30, 2021

Contact person:
Tomas Blomquist, CEO
Tel: 0705 23 01 63, tomas.blomquist@biotage.com

About Biotage

Biotage is a Global Impact Tech Company committed to solving society's problems. We offer workflow solutions and products to customers in drug discovery and development, analytical testing and water and environmental testing.

Biotage is contributing to sustainable science with the goal to make the world healthier, greener and cleaner - HumanKind Unlimited.

Our customers span a broad range of market segments including pharmaceutical, biotech, contract research and contract manufacturers as well as clinical, forensic and academic laboratories in addition to organizations focused on food safety, clean water and environmental sustainability.

Biotage is headquartered in Uppsala in Sweden and employs approx. 485 people worldwide. The Group had sales of 1,092 MSEK in 2020 and our products are sold in more than 70 countries. Biotage's share (BIOT) is listed in the Mid Cap segment on the NASDAQ Stockholm.

Website: www.biotage.com

https://news.cision.com/biotage/r/issue-and-re-purchase-of-class-c-shares-for-incentive-program,c3463529

https://mb.cision.com/Main/705/3463529/1503669.pdf

(c) 2021 Cision. All rights reserved., source Press Releases - English

All news about BIOTAGE AB (PUBL)
01/03Biotage Advances To Nasdaq Stockholm's Large Cap Segment
MT
01/03Biotage moves to the large cap segment
AQ
2021Change in number of shares and votes
AQ
2021New composition of Biotage Nomination Committee
AQ
2021Issue and re-purchase of class C shares for incentive program
AQ
2021Biotage - Change in number of shares and votes
AQ
2021Biotage AB (publ) Interim report January – September 2021
PU
2021Biotage AB (publ) Interim report January - September 2021
AQ
2021Biotage AB Reports Earnings Results for the Third Quarter and Nine Months Ended Septemb..
CI
2021BIOTAGE : appoints Nomination Committee
AQ
More news
Financials
Sales 2021 1 215 M 129 M 129 M
Net income 2021 215 M 22,8 M 22,8 M
Net cash 2021 305 M 32,3 M 32,3 M
P/E ratio 2021 55,9x
Yield 2021 0,96%
Capitalization 12 161 M 1 290 M 1 289 M
EV / Sales 2021 9,76x
EV / Sales 2022 8,46x
Nbr of Employees 478
Free-Float -
Chart BIOTAGE AB (PUBL)
Duration : Period :
Biotage AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOTAGE AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 184,30 SEK
Average target price 273,67 SEK
Spread / Average Target 48,5%
EPS Revisions
Managers and Directors
Tomas Blomquist President & Chief Executive Officer
Maja Nilsson Chief Financial Officer
Torben Vedel Stahl J÷rgensen Chairman
Jon-Sverre Schanche Chief Scientific Officer
Magnus Nordstedt Executive Vice President-IT & Digitalization
Sector and Competitors
1st jan.Capi. (M$)
BIOTAGE AB (PUBL)-30.80%1 277
SARTORIUS AG-18.64%31 853
REVENIO GROUP OYJ-20.83%1 303
VAREX IMAGING CORPORATION-16.61%1 041
CELLAVISION AB (PUBL)-9.29%751
RENALYTIX PLC-24.19%455